Work Package 9: “omics NOE” for cancer
This WP will focus on the development of a NoE fostering the integration of omic technologies into the EU healthcare systems (HCSs) to ameliorate prevention, diagnosis and treatment of cancer. Indeed, cancer is to be considered as a disease that should be prevented, early/timely diagnosed and treated appropriately within a continuum (the PDT cycle).
The specific objectives will include the definition of:
- the scope of the omics technologies “as is” and “to be”
- the scope of NoE on omics resources “as is” and “to be”
- the tasks and roles of an NoE ‘omics’
- the integration of omics NoE in the European/global omics ecosystem
- the omics NoE governance structure
- its sustainability
- its indicators of efficacy and its cost/efficacy constraintsits relationship with MSs, other EU and national networks, patients and citizen
Lead Beneficiary: SCIENSANO
Although WP9:Omics and WP10:Hitech medical resources remain separate, they have decided to work closely together. A joint meeting was held on 19 September 2023 in Paris considering the similar characteristics and common challenges in both WPs.
Endorsement criteria of NoEs on Omics and Hitech medical resources come under the following headings:
- Type and volume of activity
- Infrastructure, resources, capability
- Workflow, accessibility, collaboration
Three levels are envisaged:
- Level 1 (with some resources, possibly incomplete)
- Level 2 (intermediate)
- Level 3 (leaders in the field, mature level)
Five different subgroups of resources have been identified:
- Innovative radiotherapy
- Interventional radiotherapy
- Nuclear medicine
- Cell therapies
- Ex vivo testing of agents
The teams are working on synergies to establish the future position of the NoEs in the European cancer landscape, drawing up a common table for both WPs.
WP9 12-month update (October 2022-September 2023)